Salute e Benessere
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight
Discover the TNBC new treatment @
The triple-negative breast cancer market dynamics are expected to change in the coming years. Combining chemotherapy, immunotherapy, and targeted therapies, such as , offers enhanced disease control and expands treatment options for advanced-stage TNBC patients, while are transforming long-term management by boosting immune response, improving survival rates, and addressing the need for more effective, tailored solutions beyond first-line therapy
As potential therapies are being investigated for the treatment of triple-negative breast cancer, it is safe to predict that the treatment space will significantly impact the triple-negative breast cancer market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the triple-negative breast cancer market in the 7MM.
However, several factors may impede the growth of the triple-negative breast cancer market. TNBC is the most difficult breast cancer subtype to manage due to its aggressive nature, , and , which contribute to frequent relapse, reduced treatment efficacy, and limited long-term remission, even when diagnosed early; this underscores the that not only improve outcomes and prevent disease progression but also minimize the significant side effects of current aggressive treatments like chemotherapy and immunotherapy, which severely impact patient quality of life.
Moreover, triple-negative breast cancer treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the triple-negative breast cancer market growth may be offset by , , , and a . In addition, the about the disease may also impact the triple-negative breast cancer market growth.
Triple-negative breast cancer lacks expression of hormone receptors and HER2, rendering it unresponsive to endocrine and HER2-targeted therapies. Consequently, systemic chemotherapy has long been the mainstay of treatment, especially in metastatic settings. Management typically starts with neoadjuvant or adjuvant chemotherapy, progressing to first-line treatments in advanced stages. If the disease advances or shows inadequate response, additional lines of therapy are introduced. Immunotherapies, particularly PD-1/PD-L1 inhibitors, are increasingly being utilized in metastatic TNBC to boost the body's immune defense against cancer cells.
In early-stage TNBC, the PD-1 inhibitor has become a standard part of treatment. It is administered with neoadjuvant chemotherapy and then continued as adjuvant monotherapy. In PD-L1-positive patients (CPS ≥10), it is also used alongside chemotherapy for locally recurrent or metastatic disease. Targeted therapies are making headway as well, particularly for patients with BRCA mutations. In such cases, PARP inhibitors like target defective DNA repair pathways. , an antibody-drug conjugate (ADC) targeting TROP-2, is approved for relapsed or treatment-resistant metastatic TNBC. Although was withdrawn from the U.S. market after failing confirmatory trials, it is still available in Europe and Japan .
Taxane-based chemotherapy continues to be a cornerstone of TNBC treatment and is often combined with immune checkpoint inhibitors in PD-L1-positive cases. Platinum-based chemotherapy, though occasionally used, has shown mixed results due to concerns over toxicity and limited benefit. Despite therapeutic progress, TNBC remains a particularly aggressive subtype, underscoring the urgent need for continued innovation.
Overall, current treatments frequently fall short of achieving lasting disease control, highlighting the pressing demand for novel therapies that can improve long-term outcomes and survival for TNBC patients.
To know more about FDA-approved drugs for TNBC, visit @
Some of the drugs in the pipeline include [(Datopotamab Deruxtecan), AstraZeneca and Daiichi Sankyo], , AstraZeneca], [(Enfortumab vedotin), Astellas Pharma and Pfizer], [(L-NMMA), Galera Therapeutics], and others.
, also known as , is an experimental antibody-drug conjugate (ADC) being evaluated for the treatment of triple-negative breast cancer, both as a standalone therapy and in combination with IMFINZI (durvalumab). The therapy is aimed at high-risk TNBC patients, including those who are PD-L1-positive. Results from pivotal Phase III trials are expected in 2025, with more comprehensive findings anticipated by 2026, potentially influencing future treatment approaches for TNBC.
Currently in Phase III development for TNBC, Dato-DXd is part of a global collaboration between AstraZeneca and Daiichi Sankyo, initiated in July 2020 . Under this partnership, Daiichi Sankyo retains exclusive rights in Japan and oversees manufacturing and supply, while both companies are co-developing the drug across several cancer types globally.
, a broad nitric oxide synthase (NOS) inhibitor, is under Phase II investigation for metaplastic breast cancer (MpBC) in combination with alpelisib and nab-paclitaxel in HER2-negative metastatic or locally advanced settings. It is also being explored with a taxane in Phase II trials for patients with metastatic or locally advanced TNBC. In December 2024 , Galera Therapeutics acquired Nova Pharmaceuticals.
, an FDA-approved PD-L1 inhibitor developed by AstraZeneca for other cancers, works by blocking PD-L1 to enhance immune system recognition and destruction of tumor cells. It is currently undergoing Phase I/II studies in combination with paclitaxel and other novel therapies as a first-line option for metastatic TNBC (mTNBC), with key data expected by late 2025.
Notably, the BEGONIA trial ( October 2023 ) reported durable and significant tumor responses from the combination of datopotamab deruxtecan and IMFINZI when used as a first-line treatment for patients with mTNBC, along with a favorable safety profile.
The anticipated launch of these emerging therapies are poised to transform the triple-negative breast cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the triple-negative breast cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about triple-negative breast cancer drugs in development @
Triple-negative breast cancer is a particularly aggressive and diverse form of breast cancer that lacks expression of estrogen receptors (ER), progesterone receptors (PR), and HER2. It accounts for a substantial share of breast cancer cases and is associated with fast disease progression, high chances of recurrence, and unfavorable outcomes. TNBC tends to occur more frequently in younger women, individuals of African American descent, and those with BRCA1 gene mutations.
The risk factors for TNBC are divided into two categories: non-modifiable factors, such as age, gender, genetic mutations, family history, and breast density, and modifiable ones, which include obesity, exposure to certain chemicals, and specific drug use. Due to its aggressive behavior and absence of hormone receptors, TNBC is particularly difficult to treat, highlighting the need for continuous research to enhance therapeutic approaches and patient survival.
Diagnosis typically involves imaging tools like mammography, ultrasound, and MRI, followed by tissue sampling techniques including core needle biopsy, fine needle aspiration, or surgical biopsy. TNBC tumors are often high-grade and poorly differentiated, and the disease is staged using the TNM system, which evaluates tumor size, lymph node involvement, and the extent of metastasis.
The triple-negative breast cancer epidemiology section provides insights into the historical and current triple-negative breast cancer patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The triple-negative breast cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Download the report to understand which factors are driving triple-negative breast cancer market trends @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-L1 inhibitors companies including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PARP inhibitors companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TNBC companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key breast cancer companies including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/triple-negative-breast-cancer-market-gearing-up-for-impressive-growth-at-a-cagr-of-4-7-during-the-forecast-period-20252034--delveinsight-302515668.html